John Slevin, MD
Neurology · Lexington, KYNPI 1659319853
Payments from drug & device makers
What this record shows
UCB, Inc. accounts for 64.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $1,867 and has fallen 91.2% since, to $164 in 2025.
Across 20 payments — averaging $126.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Novocure Inc.$442
- Acadia Pharmaceuticals Inc$307
- AbbVie$91
- Stryker$64
Across 107 payments — averaging $9170.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$518K
- Sumitomo Pharma America, Inc.$184K
- UCB SA$178K
- Takeda Pharmaceuticals U.S.A., Inc.$51K
- Sunovion Pharmaceuticals Inc.$37K
- Amylyx Pharmaceuticals, Inc.$13K
What the payments were for
- Travel & lodging$1,28050%
- Food & beverage$1,25650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 9 | $1,632 |
| Novocure Inc. | 5 | $442 |
| Acadia Pharmaceuticals Inc | 4 | $307 |
| AbbVie | 1 | $91 |
| Stryker | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$268
- NUPLAZID$227
- Optune Gio$148
How this compares
$2,536 in reported general payments places this provider in the 55th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,467 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 69 | $2,541 |
| Primidone | 16 | $948 |
| Donepezil Hcl | 14 | $531 |
| Clonazepam | 36 | $151 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lexington
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Fred OdagoLexington$28K
- Zabeen MahuwalaLexington$28K
- Jagannadha AvasaralaLexington$15K
- Joshua ChalkleyLexington$15K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.